Phase 4 N=4,688 Strategic Timing of Antiretroviral Treatment
HIV Infection
Primary: Composite Endpoint of AIDS, Serious Non-AIDS Diagnoses, and All-cause Mortality — 133; 215 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Head and Neck Cancer
Primary: Median Laryngectomy-free Survival (LFS) — 11.1 months
N/A N=185 Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
Covid-19 Testing
Primary: Sensitivity and Specificity of Biozek Covid-19 Antigen Rapid Test (Saliva) — 97.5; 100 percentage - Sensitivity and specificity
Phase 3 N=366 Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) — 10.5; 10.7 months — p=0.3668
Phase 2 N=17 A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Myasthenia Gravis
Primary: Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 5; 0 Participants
N/A N=245 The Role of Pre-deployment Retraction in Decreasing Biopsy Clip Migration During Stereotactic Breast Biopsies
Breast Biopsy
Primary: Number of Breast Biopsy Patients Whose Clip Migrated Greater Than 10mm From the Biopsy Site. — 46; 44 Participants
Phase 3 N=316 Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -22.75; -23.95; -17.42 score on a scale — p=0.0136
Phase 4 N=123 AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Acne Vulgaris
Primary: Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 — -2.1; -2.1 score on a scale
Phase 4 N=62 Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine
Headache · Pregnancy Related · Occipital Nerve Block
Primary: Number of Participants With Response to Occipital Nerve Block in Pregnancy — 20; 16 Participants — p=0.30
N/A N=18,268 Improving Chronic Disease Management With Pieces
Chronic Kidney Disease · Diabetes · Hypertension
Primary: All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension — 20.7; 21.12 percentage of participants hospitalized
Phase 2 N=127 Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis
Gingival Inflammation
Primary: Incidence of Adverse Events — 19; 10; 3 Participants
N/A N=306 Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
Peripheral Arterial Disease
Primary: Number of Participants With Procedural Success — 96; 67 Participants
Phase 2 N=24 Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 1.9; 1.7 Months
N/A N=15 Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
Skin Laxity
Primary: Percent Change From Baseline of Soft Tissue Surface Area — -0.18; -017 percent change
Phase 2 N=31 Enhancing Medication-based Analgesia in Humans- STUDY 2
Pain · Cannabis · Opioid Use
Primary: Peak Cold Pressor Tolerance — 118.6; 130.8; 161.1; 163.2 minutes — p=0.195